Related Experiment Videos
Efficacy of acellular pertussis vaccine in young infants
Insights
Acellular pertussis vaccines did not prevent infection in young children during an outbreak, but significantly reduced typical symptoms. This highlights vaccine effectiveness in preventing severe pertussis disease.
Area of Science:
- Pediatric Infectious Diseases
- Vaccinology
- Epidemiology
Background:
- Pertussis (whooping cough) remains a significant public health concern, particularly for infants.
- Outbreaks in congregate settings necessitate understanding vaccine effectiveness in real-world scenarios.
Purpose of the Study:
- To evaluate the effectiveness of acellular pertussis vaccines in preventing pertussis infection and symptoms among young children during an outbreak.
Main Methods:
- A prospective study was conducted during a pertussis outbreak in a residential facility.
- Participants included 19 residents aged 2 years or younger, divided into unimmunized and acellular pertussis vaccine-immunized groups.
- Laboratory confirmation of pertussis infection (titer rise, positive culture) and symptom development were assessed.
Main Results:
- No significant difference in laboratory-confirmed pertussis infection rates was observed between unimmunized (7/10) and immunized (8/9) children.
- A significant difference was found in the development of typical pertussis symptoms, with 6/10 unimmunized children affected compared to 1/9 immunized children (P < .05).
- Bordetella pertussis isolation rates showed a trend towards difference (6/10 vs. 2/9, P = .12).
Conclusions:
- Acellular pertussis vaccination did not prevent B. pertussis infection in this population.
- However, the vaccine demonstrated a protective effect against the development of clinical symptoms in young children.
- Findings suggest acellular pertussis vaccines are effective in mitigating disease severity, even if not preventing infection entirely.
Abstract:
A prospective study of a pertussis outbreak in a residential facility was done. Among 19 residents aged < or = 2 years, 10 children were unimmunized and 9 were immunized with acellular pertussis vaccines. Of the 10 unimmunized children, 7 acquired laboratory-confirmed pertussis (four-fold titer rise, positive culture, or both); of these, 6 developed typical symptoms. Eight of the 9 immunized children acquired laboratory-confirmed infections, and 1 of these developed typical symptoms. No difference in infection was noted between the unimmunized and immunized groups (7/10 vs. 8/9, respectively), but a significant difference was observed in the development of symptoms (6/10 vs. 1/9, P < .05). Also, the isolation rate of Bordetella pertussis seemed to differ between the two groups (6/10 vs. 2/9, P = .12). In this population, acellular pertussis vaccine did not prevent infection with B. pertussis but protected most young infants from the onset of clinical symptoms.